Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sifat SharminMathilde LefortJohanna Balslev AndersenEmmanuelle LerayDana HorakovaEva Kubala HavrdovaRaed AlroughaniGuillermo IzquierdoSerkan OzakbasFrancesco PattiMarco OnofrjAlessandra LugaresiMurat TerziPierre GrammondFrancois Grand'MaisonBassem YamoutAlexandre PratMarc GirardPierre DuquetteCavit BozMaria TrojanoPamela McCombeMark SleeJeannette Lechner-ScottRecai TurkogluPatrizia SolaDiana FerraroFranco GranellaJulie PrevostDavide MaimoneOlga SkibinaKatherine BuzzardAnneke Van der WaltBart Van WijmeerschTunde CsepanyDaniele SpitaleriSteve VucicRomain CaseyMarc DebouverieGilles EdanJonathan CironAurélie RuetJérôme De SèzeElisabeth MaillartHélène ZephirPierre LabaugeGilles DeferChristine Lebrun-FrénayThibault MoreauEric BergerPierre ClavelouJean PelletierBruno StankoffOlivier GoutEric ThouvenotOlivier HeinzlefAbullatif Al-KhedrBertrand BourreOlivier CasezPhilippe CabreAlexis MontcuquetAbir WahabJean-Philippe CamdessanchéAude MauroussetIvania PatryKarolina HankiewiczCorinne PottierNicolas MaubeugeCéline LabeyrieChantal NifleDavid LaplaudNiels Koch-HenriksenFinn Thorup SellebjergPer Soelberg SoerensenClaudia Christina PflegerPeter Vestergaard RasmussenMichael Broksgaard JensenJette Lautrup FrederiksenStephan BramowHenrik Kahr MathiesenKaren Ingrid SchreiberMelinda MagyariSandra VukusicHelmut ButzkuevenTomas Kalinciknull nullPublished in: CNS drugs (2021)
Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.
Keyphrases
- multiple sclerosis
- end stage renal disease
- white matter
- newly diagnosed
- chronic kidney disease
- ejection fraction
- polycystic ovary syndrome
- prognostic factors
- peritoneal dialysis
- magnetic resonance imaging
- type diabetes
- pregnant women
- adipose tissue
- magnetic resonance
- contrast enhanced
- patient reported outcomes
- metabolic syndrome
- patient reported
- open label